T helper type 17 (Th17) cells have been characterized based on production of interleukin (IL)-17 and association with autoimmune diseases. We studied the role of Th17 cells in aplastic anemia (AA) by isolating Th17 cells from patients blood (n=41) and bone marrow (BM) mononuclear cells (n=7). The frequency and total number of CD3 + CD4 + IL-17 producing T cells were increased in AA patients at presentation in comparison with healthy controls (p=0.0007 and 0.02, respectively) and correlated with disease activity. There was an inverse relationship between the numbers of Th17 cells and CD4+CD25highFoxP3+ regulatory T cells (Treg) in the blood of AA patients.
Summary
T helper type 17 (Th17) cells have been characterized based on production of interleukin (IL)-17 and association with autoimmune diseases. We studied the role of Th17 cells in aplastic anemia (AA) by isolating Th17 cells from patients blood (n=41) and bone marrow (BM) mononuclear cells (n=7). The frequency and total number of CD3 + CD4 + IL-17 producing T cells were increased in AA patients at presentation in comparison with healthy controls (p=0.0007 and 0.02, respectively) and correlated with disease activity. There was an inverse relationship between the numbers of Th17 cells and CD4+CD25highFoxP3+ regulatory T cells (Treg) in the blood of AA patients.
Concomitant with the classical Th1 response, we detected the presence of CD4 + and CD8 + IL-17 producing T cells in a mouse model of LN infusion-induced BM failure.
Although anti-IL-17 treatment did not abrogate BM failure, early treatment with anti-IL-17 antibody reduced the severity of BM failure with significantly higher platelet (p<0.01) and total BM cell (p<0.05) counts at day 10. Recipients that received anti-IL-17 treatment had significantly fewer Th1 cells (p<0.01) and more Treg cells (p<0.05) at day 10 following LN infusion. Th17 immune responses contribute to AA pathohysiology, especially at the early stage during disease progression.
Introduction
Th17 cells have been characterized recently in mice as a novel subset of CD4 + T cells that produce Interleukin (IL)-17A (IL-17), IL-17-F and IL-22, 1, 2 and serve as immune effectors in various settings including inflammation, infection and autoimmunity 3, 4 . Th17 cells produce a large amount of IL-17A, a cytokine that coordinates tissue inflammation by inducing the expression of proinflammatory cytokines (such as IL-6 and TNF), chemokines (such as KC, MCP-1 and MIP-2), and matrix metalloproteases that mediate tissue infiltration and tissue destruction. 5 In mice, the differentiation program of Th17 cells from naive CD4 + T cells requires the activation of the transcription factor, orphan nuclear receptor RORγt 6 , and the presence of IL-6 and transforming growth factor-β (TGF-β) 7, 8 . In humans, Th17 differentiation is under the control of IL-1β, IL-6, and IL-23. 9, 10 Several studies have reported the association of IL-17 with inflammatory disorders such as rheumatoid arthritis, asthma, multiple sclerosis and lupus, 11 as well as hematological disorders such as myelodysplastic syndrome 12, 13 and acute myeloid leukemia. 14 Aplastic anemia (AA), a disease characterized by peripheral blood pancytopenia and bone marrow (BM) hypoplasia, 15 is an immune-mediated disorder in most cases with active destruction of hematopoietic cells by effector T lymphocytes. 16 Recovery of autologous hematopoiesis in patients who failed to engraft after conditioning and stem cell transplantation, 17 and responsiveness of patients to immunosuppressive therapies 18 , provided powerful evidence for the pivotal role of the immune system in the disease pathophysiology. Immoderate production of interferon-γ (IFN-γ), tumor necrosis factor For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From alpha (αTNF), and interleukin-2 (IL-2) from patients' T cells suggests that the hematopoietic cells are destroyed through a Th1 response [19] [20] [21] , as illustrated by the upregulation of the transcription factor T-bet in patient T cells 22 . The description of nonrandom skewing of the Vβ chain families of the T-cell receptor in patient peripheral blood (PB) revealed that expanded oligoclonal or monoclonal specific Vβ subfamilies selectively induced apoptosis of hematopoietic progenitor cells. 23 Regulatory T (Treg) cells, which control and suppress auto-reactive T cells, are decreased at disease presentation in almost all patients. 24 We have developed murine models for immune-mediated BM failure by the infusion of allogeneic lymph node (LN) cells into sublethally-irradiated recipients for which, treatment with limited number of Treg cells 25 , or anti-IFN-γ and anti-TNFα antibodies 26 , effectively mitigated BM destruction. By using T-bet-deficient LN cells as effectors, we recently found that lack of Th1 immune response due to T-bet deficiency significantly abrogated the immune responses, but recipient mice still experienced mild BM destruction. 27 Since Th17-mediated immune responses have been reported in autoimmune disorders, we hypothesized that Th17 cells could contribute to the development of BM failure in mice, like in some AA patients. 28 However, a recent report showed a very limited role of Th17 cells in AA patients 29 while other studies revealed reciprocal developmental pathways for the generation of pathogenic effector Th17 and Treg cells. 8, 30 Here we examined the role of Th17 immune responses in AA by assessing Th17 and Treg cells presence in AA patients before and after immunosuppressive therapy and by testing the preventive/therapeutic effects of anti-IL-17 antibody in abrogating BM destruction in our mouse model. Results from this study 
Patients and methods

Patient information
Heparinized PB and/or BM samples were collected from 41 patients (age range 18-82 years) with acquired AA after informed consent in accordance with approved protocols by the institutional review board of the National Heart, Lung and Blood Institute and the Declaration of Helsinki. The diagnosis of AA was based on the criteria of the International Agranulocytosis and AA Study. Blood samples from 10 healthy volunteers (age range, 18-60 years) were used as controls. All patients and controls had normal BM cytogenetics. For young adults (under 40 years of age), chromosomes were assayed after in vitro exposure of lymphocytes to diepoxybutane and to mitomycin C to exclude Fanconi anemia. All patients were screened for telomerase mutation and tested for paroxysmal nocturnal hemoglobinuria by flow cytometry (positive in case of. absence of glycosylphosphatidylinositol (GPI)-anchored proteins on more than 1% of neutrophils or red cells). Patients were divided into three groups: 1) De novo: PB (n = 21) and BM (n = 7) samples were obtained from patients at time of diagnosis before any treatment;
2) Complete remission (CR): Samples were obtained from 13 patients in long term CR with normal complete blood counts without further treatment; 3) Poor responders (PR): Samples were taken from 16 patients who had responded poorly to treatment. Clinical information is summarized in Table 1 .
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Mice and cell preparation
Inbred C57BL/6J (B6) and hybrid (B6 × BALB/cBy)F1 (CByB6F1) mice were obtained from the Jackson Laboratory (Bar Harbor, ME), and were bred and maintained in the NIH animal facility under standard care and nutrition. Mice were used at 2-6 months of age and were gender-matched between donors and recipients in each experiment. All animal studies were approved by the National Heart, Lung, and Blood Institute's Animal Care and Use Committee. Blood was obtained through retro-orbital sinus bleeding.
Inguinal, brachial, and axillary LNs were obtained from B6 mice, homogenized using a cell grinder, washed in IMDM, filtered through 90-μM nylon mesh to obtain single cell suspension, and counted using a ViCell counter (Coulter Cooperation). BM cells were extracted from bilateral femurs and tibiae.
Induction of BM failure
LN cells from B6 donors were infused into CByB6F1 mice at 5 × 10 6 cells per recipient to induce BM failure as previously described. 25, 26 All recipient mice received a sub-lethal dose of 5 Gy Total Body Irradiation (TBI) from a Shepherd Mark 1 137 cesium gamma irradiator (J. L. Shepherd) 6 hours before cell infusion. In each experiment, mice that received 5 Gy TBI only without LN cell infusion and/or mice received no treatment were used as controls. Animals were bled at 7, 10, 15 and 19 days after LN cell infusion for complete blood counts (CBC) using a Hemavet 950 analyzer (Drew Scientific), and
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Immunohistochemistry and confocal microscopy
BM was obtained from a biopsy core, extracted from the posterior iliac crest of AA patients. BM, encased in bone, was lightly fixed in paraformaldehyde (PFA), and then permeabilized in 0.05% Triton X-100 (Sigma). BM whole mount specimens were incubated with AB blood type serum in order to block non-specific binding. The samples were incubated with the anti-IL17 primary antibodies (eBiosciences), and then with FITC-labeled secondary antibodies. Additional stains used DAPI (Invitrogen) for nuclei.
Samples were washed 3 times with phosphate-buffered saline (PBS) between each staining and were subjected to confocal microscopy within a few hours. Images were acquired by CLSM with the Zeiss LSM 710 systems (Carl Zeiss MicroImaging).
IL-17 depletion in vivo
To neutralize IL-17, 100 μg of anti-mouse IL-17 monoclonal antibody (clone 50104, R&D systems) was re-suspended in phosphate-buffered saline (PBS) and then injected intraperitoneally into each mouse every 2 days for a total of 4 injections starting from day -3 (early treatment: days -3, -1, 1, and 3) or day 7 (late treatment: days 7, 9, 11 and 13) of LN cell infusion. Mice that received TBI only and TBI + B6 LN cell infusion without anti-IL-17 antibody injection were used as controls. Recipients were euthanized at day 
Pathology
Sternebrae were fixed in 10% neutral buffered formalin and embodied, sectioned, and H&E stained (Histoserve Inc., Germantown, MD). Slides were viewed using an Olympus IX50 microscope (Optical Elements), and photographic images of BM morphology were captured at 4x and 10x magnification using a SPOT INSIGHT camera with the SPOT version 4.0.8 software.
ELISA
Blood was collected by orbital sinus bleeding into tubes containing 10 μ L 0.5M EDTA and centrifuged at 1000g for 10 minutes. Plasma was removed and stored at -20°C.
Plasma cytokine concentrations were measured using the Multi-Analyte ELISArray™ Kits (SABiosciences) as previously described 32 .
Statistical Methods
Summary statistics, such as percents, medians, means, standard deviations, and 95% confidence intervals, were used to describe the patients' baseline characteristics and mice samples. Pairwise comparisons between groups were conducted using Student's t-tests and further verified by the Wilcoxon tests based on ranks. The t-test p-values were reported for all the pairwise comparisons and compared with the 5% statistical significance level. When multiple groups are present, the analysis of variance (ANOVA) models and the ANOVA F-tests were employed to evaluate the overall differences among these groups. Multiple linear regression models were used when continuous independent variables or covariates were present. Numerical results were computed using the S-plus 8 statistical software package (TIBCO). Significance level was set at 5% for all the statistical tests.
Results
Th17 cells in the BM of AA patients
To define the role of Th17 cells in the development of AA, we first stained BM samples from 2 AA patients (1 moderate and 1 severe AA) and analyzed the images using a confocal microscope. Patient samples showed notable decrease in BM cellularity with an increased presence of IL-17 + cells in comparison to samples from controls ( Figure   1A ). We then isolated and stimulated BMMNCs with PMA and ionomycin in the presence of monensin from patients (n = 7) and controls (n = 4). Because of reduced CD4 expression after stimulation in human samples, we focused on CD3 + CD8 -IL-17 + T cells as Th17 cells 31 and identified a population of CD3 + CD8 -IL-17 + T cells (Th17 cells) in patient samples ( Figure 1B ), which was significantly (P = 0.04) larger than in healthy controls (3.3 ± 2.1% versus 1.3 ± 0.2%, Figure 1C ). We also assessed the presence of Th17 cells in the PBMCs and found that the increased expression of intracellular IL-17 in BMMNCs and PBMCs was highly correlated (r = 0.939, P < 0.01) among patients but not among controls ( Figure 1D ).
Association of Th17 cells with disease activity
In AA, IFN-γ is a marker of the Th1/cytotoxic T cells (Tc1) immune response that has been directly implicated in hematopoietic cell destruction. 16 We assessed Th1/Tc1 and Th17 responses in our cohort of AA patients (21 at diagnosis, 13 in CR, and 16 in PR)
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We further assessed Th17 contribution to AA. The percentage of CD3 + CD8 -IL-17 + T cells (Th17 cells) was measured by flow cytometry after stimulation with PMA and ionomycin, and was detectable in all groups of patients ( Figure 2A ). The percentage of Th17 cells was significantly higher (P < 0.001) in the 21 newly diagnosed AA patients (2.3 ± 1.5%) than in the 10 healthy controls (0.6 ± 0.3%; Figure 2B ), resulting in a significantly higher (P < 0.01) Th17 T cell concentration in patients (11.2 ± 7.6 × 10 6 /L) than in controls (5.1 ± 2.9 × 10 6 /L, Figure 2C ). Patients with moderate AA had higher proportion and higher circulating number of Th17 T cells (3 ± 1.7% and 15.9 ± 9.4 × 10 6 /L) than did patients with severe AA (2.2 ± 1.4% and 10 ± 7.1 × 10 6 /L), but these differences were not statistically significant. We did not find any difference in the frequency and number of Th17 cells according to the PNH status. Among the 16 patients who received treatment, 11 responded at 6 months (69%; 6 CR and 5 partial remissions). The initial pre-treatment proportion and absolute number of Th17 cells were respectively 2.5 ± 1.6% and 11.2 ± 7.2 × 10 6 /L in responders compared with 1.7 ± 0.2% and 8.2 ± 6.5 × 10 6 /L in non-responders (not statistically significant). We then compared the proportion and absolute number of Th17 T cells in patients at diagnosis with patients in CR ( Figure 2B and 2C). Patients in CR had lower proportion and fewer absolute number of Th17 cells than patients at diagnosis (0.6 ± 0.3% and 3.7 ± 2.9 × 10 6 /L versus 1.1 ± 0.7% and 5.1 ± 2.9 × 10 6 /L; P = 0.02 and P < 0.01, respectively).
Proportions and absolute numbers in PR patients are indicated (Figures 2B and 2C).
We measured Th17 cell presence in 10 patients (5 in CR and 5 as PR) before and after treatment. All 5 patients in CR had marked decreases in the proportion and absolute number of Th17 cells following treatment ( Figure 2D ). In the 5 PR patients, 4 of them showed an increased proportion of Th17 T cells ( Figure 2E 
Inverse relationship between Th17 and Treg cells in patients with AA
Treg cells play a fundamental role in the maintenance of immune tolerance to prevent autoimmune diseases. A reciprocal developmental pathway for the generation of pathogenic Th17 cells and protective Treg has been reported. 8 Treg cells were defined in the current study by the cell surface phenotype CD4 + CD25 high and the intracellular marker FOXP3. 32 We found that Treg cell percentage was decreased in AA patients at diagnosis, as we have reported previously. 24 We analyzed the correlation between the proportion of natural Treg cells and Th17 cells comparing patients at diagnosis, in CR and in PR (Figure 3 ). Using a linear regression model, we found that healthy controls had higher proportion of Treg cells and lower proportion of Th17 cells than did patients at diagnosis, also showing different distribution patterns (P < 0.001). Using the same model, we found also different distribution patterns regarding patients at diagnosis and CR patients (P < 0.01). Moreover, this difference diminished but was still significant positive CD4 + cells in B6 LN-cell-infused animals (15.0 ± 1.1%) was significantly higher (P < 0.01) than that in TBI-only controls (6.5 ± 1.3%). Almost no IL-17A positive CD4 + cells were detectable in untreated animals ( Figure 4A, upper panels) . Similarly, the proportion of IL-17A positive CD8 + T cells was also significantly higher (16 ± 2.3%, P < 0.01) in B6 LN-cell-infused mice than in TBI-only controls (6.0 ± 1.3%). Again, this population was barely visible in untreated animals ( Figure 4A , lower panels). This difference along with the overall T cell expansion resulted in a 32-fold increase in total IL-17A + CD4 + T cells and a 28-fold increase in total IL-17A + CD8 + T cells in the BM of B6 LN cell infused animals than in TBI only controls ( Figure 4B ). We also noted that the majority of IL-17A + T cells were Th17 specific and only minor fractions of CD4 + and CD8 + T cells were IL-17A + IFN-γ + double positive ( Figure 4C ). Figure 6C ). Delayed anti-IL-17 antibody treatment to day 7 after LN cell infusion had much less effect, as histological analysis (correlated with blood count) revealed severe loss of BM cellularity in these animals ( Figure 6B-C) . We also did not find any difference at day 16 between mice that received early anti-IL-17 treatment and mice that injected with LN without anti-IL-17 treatment (data not shown), as both groups had BM hypocellularity, consistent with the notion that early anti-IL-17 treatment is capable of 
Treg cell up-regulation and Th1 down-regulation following anti-IL-17 treatment
To further understand the mechanism underlying the effect of early anti-IL-17 treatment in our BM failure model, we analyzed the contribution of different T-cell populations and activation markers during induction of disease. We did not find any difference in the expansion of CD4 + and CD8 + T cells with or without anti-IL-17 treatment (data not shown). As expected, we observed a significant, 5-fold decrease of Th17 cells (P = 0.01) and 2-fold decrease (P = 0.01) in CD8 + IL-17 + T cells in mice that received early anti-IL-17 treatment ( Figure 7A ). Early anti-IL-17 antibody treatment also caused a significant (P = 0.01) decrease in IFN-γ + CD4 + T cells ( Figure 7A ). At day 10 after LN injection, there was a significant increase (P = 0.04) in the percentage of donor-derived CD4 + FoxP3 + T cells in recipients that received the anti-IL-17 treatment ( Figure 7B ). We also analyzed cytokine levels in the plasma on day 10 after LN injections and found decreased levels of IL-6 (P = 0.15) and IFN-γ (P = 0.29) in the plasma of recipients that received anti-IL-17 neutralization ( Figure 7C ).
Discussion
In the current study, we first confirm the role of Th1/Tc1 immune response in AA development and then characterized the involvement of Th17 cells in the pathophysiology of AA. We found an increased number and frequency of Th17 cells in BMMNCs and PBMNCs in patients with AA at diagnosis along with a reduction in Treg cells. In patients who responded to treatment, we found that number and frequency of Th17 cells were both comparable to healthy controls, concomitantly with Treg recovery.
In a mouse model of BM failure, we found expansion of IL-17 producing T cell during the induction of the disease. Early treatment with anti-IL-17 antibody reduced the severity of BM failure at day 10 but not at day 16, illustrating that Th17 immune responses may contribute to the recruitment of Th1 cells and may be important for the proinflammatory cytokine milieu in the BM during the early stages of BM failure.
Until now, the potential role of IL-17 in the pathophysiology of AA is still discussed. A previous study in humans showed elevated expression of IL-17A mRNA in BM and PB mononuclear cells in 28 patients with severe AA before any specific therapy, 28 which is concordant with our findings. However, others found no difference in the frequencies and numbers of Th17 cells between patients with AA and healthy controls. 29 We speculate that the presence of moderate AA patients in our cohort, displaying a higher number of Th17 cells than did patients with severe AA, may have Immune and autoimmune responses are regulated by a fine balance between effector and regulatory T cells. In AA, 30% of patients showed autoreactivity and 50% showed alloreactivity in lymphocyte toxicity assays using autologous or HLA-identical target cells 39 . Treg cells are decreased in most patients with AA 24 and infusion of Treg cells in a minor antigen H60-mediated AA mouse model aborted H60-specific T-cell expansion and prevented BM destruction. 25 We found an inverse correlation between Treg and Th17 cells in AA patients at diagnosis. Our results are in accordance with the For personal use only. on November 16, 2017. by guest www.bloodjournal.org From dichotomy already reported in the generation of pathogenic Th17 cells responsible for autoimmunity and Tregs that inhibit autoimmune tissue injury. 8 Our findings support the notion that the immune system is polarized through a Th1/Th17 response during the induction of BM failure with a Treg deficiency leading to the increased autoreactive T cell activity and the development of clinical AA.
Our study also raises some questions concerning PR patients. We used stringent criteria to classify patients into different groups in which patients in CR all had normal CBC at the time of sampling while PR patients had been highly treated before sampling. While the proportions of Th1/Tc1 or Th17 cells were significantly different between PR and CR patients and normal individuals, the absolute numbers of these cell subsets were not different among different groups. Moreover, 5 patients showed a roughly normal balanced Th17/Tregs distribution while being poor responders (Figure 3 ).
It is possible that the autoimmune insult was adequately suppressed with therapy in these patients but that the destruction of primitive hematopoietic elements was such that precluded resumption of more efficient hematopoiesis. In our mouse model for LN infusion-induced BM failure, 25,33 we knew from a previous study that T-bet deletion did not completely abolish the ability of LN cells to induce BM damage. 27 Th17 cells became a good candidate to explain this feature since either Th17 or Th1 effectors response can drive autoimmunity. 40 Besides the classical Th1 response, we detected both CD4 + IL-17 + and CD8 + IL-17 + T cells during the induction of the disease. This latter subset has been identified in mice and in humans. 41, 42 We did not find CD8 + IL-17 + T cells in our cohort of SAA patients, which does not suggest a role of this subset in the pathophysiology of the disease in human.
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From In our mouse model, we were able to deplete effectively both IL-17 producing T cell subsets with anti-IL-17 antibody and showed that early depletion delayed BM failure onset and reduced severity. Nevertheless, later IL-17 cells depletion did not modify the course of BM failure. These results indicate that Th17 cell populations are involved in the initiation of the disease. While IL-17 could be produced by either CD4 + or CD8 + T cells, we were unable to separately deplete either of the two cell subsets. While it has been shown that CD8 + IL-17 + T cells do not express granzyme B and could not mediate cell lysis in vitro 43 , those cells could be critically-important effectors in the pathogenesis of autoimmune disease 42 or in CD8 + T cell-based adoptive immunotherapy 44 . Altogether, it is possible that Th17 cells might be generated more rapidly than Th1 cells during inflammation, and that Th17 cells might participate in the initial acute inflammation, whereas Th1 cells might function to prolong and perpetuate tissue destruction. 4 We then explored the impact of Th17 depletion on the immune system in our mouse model of BM failure. Mouse treated with anti-IL-17 have a decrease frequency and absolute number of donor-derived Th1 cells in the BM at day 10 while no change was observed at day 16 (data not shown). We also found a not significant decrease in IFN-γ level at day 10 in the plasma of the mouse who received LN injection and anti-IL-17. Those data are very similar to the recipients of IL-17 -/-CD4 + T in a graft versus host disease model 45 and correlate with other studies regarding IL-17 and recruitment of Th1 cells 46, 47 . Collectively, these data suggest that IL-17 may directly or indirectly modulate Anti-IL-17 treatment could thus be evaluated in patients with AA to shift the balance between Treg and Th17 cells, in order to restore the function of Treg cells in severe AA. 
